Between 2010 and 2014, 37 new molecular entities were approved by the FDA for the treatment of cancer; and between 1995 and 1999, only 20 such agents were approved. Michael Kurman, MD, from INC Research shares his thoughts on Phase 1 Clinical Trials in an Era of Increasing Oncologic Success.
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte